FIG. Typical standard curve before (e) and after (0) freeze-drying the reagents.
stored at -2OCC. Reagents A, Band MTX standards were stable in the frozen state for at least three months.
Immediately before use, an aliquot of reagent A and reagent B were reconstituted in 0·9 mL and 1·5 mL, respectively, of a 0·1 M phosphate buffer, pH 7·1 containing 14 mmol dithiothreitol. MTX standards, blank or clinical plasma samples (50 ul.) were diluted with 250 ul, of buffer and reagent A (50 ul.) was added after dilution with 250 ul, of buffer. After a delay of 15 s, the reaction was started by the addition of 50 ul, of reagent B plus 250 ul, of buffer. The decrease in optical density (~E) was measured over three minutes at 340 nm and 30 cC using either a Beckman 35 or a Gilford 3500 spectrophotometer. For a more rapid assay, the latter instrument coupled with a Syva Carousel on a two-point mode with a 10 s delay and a 30 s measuring time at 37 cC was used.
Although freeze-drying resulted in approxic 004 , 6 8 10
It is now generally accepted that monitoring the plasma decline, of methotrexate (MTX) after high-dose infusion therapy is an essential requirement for good patient management. Although a rapid EMIT assay for MTX is commercially available (Syva, Maidenhead, Berkshire, England) and is being extensively used, the sensitivity of this method (2x 1O-7 M) appears to be inadequate t and the cost of a single MTX determination is high. A dihydrofolate reductase inhibition assay for MTX has previously been showrr' to be useful for the identification of patients likely to develop druginduced toxicity after high-dose infusion therapy. The present report describes a modification of the enzyme inhibition assay which can be adapted for use in routine biochemical laboratories.
Reagent A was prepared by the addition of cold distilled water to five units of bovine dihydrofolate reductase (Sigma Chemical Company, Poole, Dorset, England, Cat No D6385) giving a final volume of 2·2 mL. Ten milligrams of NADPH (Sigma, Chemical Company, Cat No N7505) was made up in 1·0 mL cold distilled water. Fifty ul, of the diluted enzyme suspension and 100 ul, of co-enzyme solution were mixed and the reagent immediately frozen at -70 cC. Reagent B consisted of 25 mg dihydrofolate acid (Sigma Chemical Company, Cat No D7006) suspended in 10 mL cold 0·OD5 NHC1 containing 14 mmol dithiothreitol and 200 ul, aliquots frozen immediately at -70 cC. Both reagents were lyophilised using a Freezemobile 3 (Virtis, New York, USA) at -60 C C with an evacuation pressure of 35 millitors. The aliquots, each sufficient for eighteen MTX determinations, were stored at -20 cC. Methotrexate either in powder form (Lederle Laboratories, Hants, England), or as a standard solution (Syva, Maidenhead, Berkshire, England), was diluted with water to cover a calibration range of 1x 10-8 to 1X 1O-7 M and aliquots of these solutions were Dihydrofolate reductase inhibition assay for MTX 613 mately a 30% fall in enzyme activity, MTX calibration curves obtained before and after lyophilisation of the reagents were similar ( Fig.) . Using plasma samples obtained from patients, there was a good correlation with this method of MTX assay and the EMIT assay (y=1'003 x-0 '274, r=0'975, n=62) but the sensitivity of the former method was lO-fold greater than the latter. The cross-reactivity of the major metabolite, 7-hydroxymethotrexate was 3·6% for both assays.
